support this site

Thursday, September 20, 2007

Launching nanoparticle drug delivery site

Here is the start of my site devoted to nanoparticle drug delivery. I am providing it as a service so that fewer people will need to buy overpriced market reports on the same subject. I will also launch several other sites on near term nanotechnology subjects. My main website on future technology with a significant focus on advanced nanotechnology is advancednano

The Drug delivery is a multi-billion dollar business. Some calculate it as a 9.8 billion business. Led by the strong growth of biotechnology drugs requiring novel delivery technologies, the injectable/implantable drug delivery market reached revenues of $9.8 billion in 2006

Nanotechnology in drug delivery

A drug delivery website

Drug delivery stocks

The 9th annual drug delivery symposium coming Dec 16-20, 2007 is only about $600 versus $5000 or more for some market reports

Advance Nanotech Singapore Pte. Ltd. owns 75% of Nano Solutions Limited (Imperial College, London) which is developing Nanovindex. Nanovindex is a nanoparticle-hydrogel composites for drug delivery.

From 2005, 10Q
Nanotechnologies have already begun to change the scale and methods of drug delivery and hold huge potential for future developments in this area. Nanotechnology can provide new formulations and routes for drug delivery that broaden their therapeutic potential enormously by allowing the delivery of new types of medicine to previously inaccessible sites in the body. Novel composites incorporating nanoparticles are particularly exciting for these applications. A key to gaining competitiveness within the market is to develop next generation composites which are extremely sensitive to a variety of environmental stimuli. NanoVindex aims to achieve this by utilising expertise in rational peptide design to incorporate specific pH, enzymes and temperature triggers within the composites enabling a new level of control over the release of encapsulated drugs.


NanoVindex is seeking to develop a platform technology of nanoparticle-hydrogel composites for tailored drug delivery applications. The development shall leverage the research of Imperial College London in rational design of self-assembling peptide systems, control over the nanoscale organic/inorganic interface, and physiologically responsive bio-nano materials. Revenues to drug delivery companies were $1.3bn in 2002 and projected to increase to $6.7bn by 2012. With the focus evermore on emerging nanotechnologies and the improvements these may offer over more conventional systems, the market for new nanotechnologies in drug delivery is poised to be a multi-billion dollar arena. These technologies have the potential to revolutionise the pharmaceutical industry.

Abstract on Hydrogel-Nanofiber Composite Systems For Drug Delivery

2003 patent, Composite hydrogel drug delivery systems

google search of hydrgel composites drug delivery

Google search on nanoparticle drug delivery

Other drug delivery market studies by Kalorama